Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | MGAM | O43451 | 2/20 | 0.49 |
| ▸ | SI | P14410 | 2/20 | 0.49 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.49 |
| ▸ | AMY1A | P0DUB6 | 4/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.47 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.47 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7280607 | 0.83 | KDM4E (0.50) | PDE2AKDM4ECYP1A2CYP3A4GAA | |
| SCHEMBL3337825 | 0.80 | PDE2A (0.66) | PDE2AKDM4EGAAAMY1ASMN1; SMN2 | |
| SCHEMBL13405983 | 0.80 | PIN1 (0.53) | KDM4ECYP1A2CYP2C9CYP2B6SMN1; SMN2 | |
| SCHEMBL13405986 | 0.77 | NQO2 (0.46) | KDM4EAMY1ASMN1; SMN2MEN1POLB | |
| SCHEMBL6040494 | 0.76 | PDE2A (0.65) | PDE2AKDM4ECYP1A2CYP3A4CYP1A1 | |
| SCHEMBL11657032 | 0.76 | CYP1A1 (0.49) | PDE2AKDM4ECYP1A2CYP3A4GAA | |
| SCHEMBL23743251 | 0.75 | GUSB (0.72) | KDM4ECYP1A2CYP1A1CYP1B1MEN1 | |
| SCHEMBL13405981 | 0.75 | NPC1 (0.69) | KDM4EGAAMGAMSIMGAM2 | |
| SCHEMBL12470674 | 0.75 | PDE2A (0.56) | PDE2AKDM4ECYP1A2CYP3A4GAA | |
| SCHEMBL10734755 | 0.73 | PDE2A (0.57) | PDE2AKDM4ECYP1A2CYP3A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705031-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705031-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-27 | — | — | US | disclosed |
| US-20080306129-A1 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-20080306129-A1 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-7309716-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309716-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306129-A1 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | KCNJ11, KCNJ1, KCNJ2 | PDE2A 1020/4885KDM4E 1468/4885CYP1A2 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.